Find Clinical Trial

Home » Find Clinical Trials » Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).

Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).

← Back

Study Phase	Phase 3

Therapeutic Area	Neuropsychiatric Diseases

Indication	Generalised Anxiety Disorder

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	AGOMELATINE, S020098

Active Substance Code	S020098

Protocol Code	CL3-20098-050

EudraCT Code	2006-005674-47

ISRCTN Code	ISRCTN38094599

Documents and links

Results summary	READ MORE

Scientific publication	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.